Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer
1996

Epirubicin, Cisplatin, and 5-Fluorouracil for Gastro-Oesophageal Cancer

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): AA Melcher, D Mort, TS Maughan

Primary Institution: Velindre Hospital

Hypothesis

Can neoadjuvant chemotherapy with ECF improve surgical outcomes in gastro-oesophageal cancer?

Conclusion

Neoadjuvant ECF chemotherapy showed a 56% response rate but did not achieve complete pathological responses.

Supporting Evidence

  • 62% of assessable patients had symptomatic improvement on chemotherapy.
  • 56% of patients showed objective evidence of tumour response.
  • 67% of patients proceeded to surgery after chemotherapy.

Takeaway

Doctors used a special medicine to help patients with stomach and esophagus cancer before surgery, and it helped some feel better, but it didn't completely remove the cancer in any cases.

Methodology

Patients received ECF chemotherapy every 3 weeks for four cycles, followed by assessment for surgery.

Potential Biases

Potential misclassification of resectability based on initial assessments.

Limitations

Accurate staging of tumours was challenging, and the study had a small sample size.

Participant Demographics

{"male":22,"female":5,"mean_age":54,"age_range":"29-71"}

Statistical Information

Confidence Interval

95% confidence interval 58-100% for three-year survival in patients achieving complete resection.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication